HDAC9 and non-small cell lung carcinoma: We next used pharmacological inhibitors such as vorinostat (pan-HDAC inhibitor) and tubastatin A (HDAC6-selective inhibitor) to validate that suppression of HDAC6 activity increases cisplatin-induced DNA damage in NSCLC cells.